Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Shukla SD | Platelet activating factor-stimulated formation of inositol triphosphate in platelets and its regulation by various agents including Ca2+, indomethacin, CV-3988, and forskolin. | 1985 | Arch. Biochem. Biophys. | pmid:3875314 |
Billah MM et al. | Platelet-activating factor metabolism in human amnion and the responses of this tissue to extracellular platelet-activating factor. | 1985 | Prostaglandins | pmid:3936121 |
Sturk A et al. | Synergistic effects of platelet-activating factor and other platelet agonists in human platelet aggregation and release: the role of ADP and products of the cyclooxygenase pathway. | 1985 | Thromb. Res. | pmid:2934863 |
Zukowska-Grojec Z et al. | The adrenergic system and the cardiovascular effects of platelet activating factor (1-0-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine) in SHR and WKY rats. | 1985 | Clin Exp Hypertens A | pmid:2994912 |
Shen TY et al. | The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor. | 1985 | Int J Tissue React | pmid:2997065 |
Sánchez Crespo M et al. | Synthesis of platelet-activating factor from human polymorphonuclear leukocytes: regulation and pharmacological approaches. | 1985 | Int J Tissue React | pmid:2997066 |
Proll MA et al. | Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein, Ni. | 1985 | Mol. Pharmacol. | pmid:2997592 |
MacIntyre DE et al. | Endogenous and pharmacological mechanisms for the regulation of human platelet cytosolic free Ca2+. | 1985 | Nouv Rev Fr Hematol | pmid:2997706 |
Lachachi H et al. | Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021. | 1985 | Biochem. Biophys. Res. Commun. | pmid:2998370 |
Hemmendinger S et al. | [Physiology of the interactions of blood and the blood vessel wall. Role of pharmacologically active lipids]. | 1985 | Arch Mal Coeur Vaiss | pmid:3938941 |
Hwang SB et al. | trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. | 1985 | J. Biol. Chem. | pmid:2999126 |
Iñarrea P et al. | Synthesis of PAF-acether and blood volume changes in gram-negative sepsis. | 1985 | Immunopharmacology | pmid:3886598 |
Lellouch-Tubiana A et al. | Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. | 1985 | Br J Exp Pathol | pmid:3890915 |
Weber N and Mangold HK | Semi-synthetic preparation of 1-O-[1'-14C]hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) using plant cell cultures. | 1985 | J. Lipid Res. | pmid:3891896 |
Hanahan DJ and Weintraub ST | Platelet-activating factor isolation, identification, and assay. | 1985 | Methods Biochem Anal | pmid:3894881 |
Zimmerman GA et al. | Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin. | 1985 | Circulation | pmid:3928193 |
Mallet AI and Cunningham FM | Structural identification of platelet activating factor in psoriatic scale. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3970690 |
Valone FH | Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). | 1985 | Biochem. Biophys. Res. Commun. | pmid:3970703 |
Camussi G and Brentjens JR | Inhalation of horseradish peroxidase by rabbits with specific IgE antibodies results in release into the circulation of platelet-activating factor and in lung lesions. | 1985 | Clin. Immunol. Immunopathol. | pmid:3971603 |
Darius H et al. | Beneficial effects of a new potent and specific thromboxane receptor antagonist (SQ-29,548) in vitro and in vivo. | 1985 | J. Pharmacol. Exp. Ther. | pmid:2997428 |
Chesney CM et al. | Desensitization of human platelets by platelet activating factor. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3977920 |
Nakayama R et al. | Generation of acetyl glyceryl ether phosphorylcholine from the rat skin and muscle tissues stimulated by moxibustion. | 1985 | Biochem. Biophys. Res. Commun. | pmid:3977939 |
Archer CB et al. | Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man. | 1985 | Br. J. Dermatol. | pmid:3978036 |
Gerdin B et al. | Permeability-increasing ability of PAF-acether in rat skin. | 1985 | Inflammation | pmid:3980073 |
Emeis JJ and Kluft C | PAF-acether-induced release of tissue-type plasminogen activator from vessel walls. | 1985 | Blood | pmid:3924144 |
Benveniste J and Chignard M | A role for PAF-acether (platelet-activating factor) in platelet-dependent vascular diseases? | 1985 | Circulation | pmid:3928192 |
MacIntyre DE et al. | Tumour-promoting phorbol esters inhibit agonist-induced phosphatidate formation and Ca2+ flux in human platelets. | 1985 | FEBS Lett. | pmid:2981715 |
Ludwig JC et al. | Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin. | 1985 | Arch. Biochem. Biophys. | pmid:4037794 |
Surles JR et al. | Facile synthesis of platelet-activating factor and racemic analogues containing unsaturation in the sn-1-alkyl chain. | 1985 | J. Med. Chem. | pmid:4038418 |
Aul C et al. | [Thrombotic thrombocytopenic purpura]. | 1985 | Klin. Wochenschr. | pmid:4038757 |
Hanahan DJ et al. | A novel approach to structure proof of glyceryl ether-containing glycerophospholipids. Base-catalyzed methanolysis of platelet-activating factor (AGEPC) at 60 degrees C. | 1985 | J. Lipid Res. | pmid:4067422 |
Atkins JN | Platelet-aggregating factor in thrombotic thrombocytopenic purpura. | 1985 | Ann. Intern. Med. | pmid:4038861 |
Klöcking HP et al. | Release of tissue-type plasminogen activator by platelet-activating factor. | 1985 | Thromb. Res. | pmid:4040278 |
Pedersen AK and FitzGerald GA | Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. | 1985 | Clin. Pharmacol. Ther. | pmid:3917387 |
Kilpatrick JM and Virella G | Inhibition of platelet-activating factor by rabbit C-reactive protein. | 1985 | Clin. Immunol. Immunopathol. | pmid:4042435 |
Monnens L et al. | Platelet aggregating factor in the epidemic form of hemolytic-uremic syndrome in childhood. | 1985 | Clin. Nephrol. | pmid:4042442 |
Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
Page CP et al. | Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. | 1985 | Agents Actions | pmid:4003195 |
Page CP et al. | Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. | 1985 | Agents Actions | pmid:4003196 |
Spicer BA et al. | An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. | 1985 | Agents Actions | pmid:4003197 |
Sandler RM et al. | Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG. | 1985 | Am. J. Clin. Pathol. | pmid:4003343 |
Tencé M et al. | Ether-phospholipid composition in neutrophils and platelets. | 1985 | Thromb. Res. | pmid:4024039 |
Oda M et al. | Production of platelet-activating factor by washed rabbit platelets. | 1985 | J. Lipid Res. | pmid:3934305 |
O'Neill C et al. | Maternal recognition of pregnancy prior to implantation: methods for monitoring embryonic viability in vitro and in vivo. | 1985 | Ann. N. Y. Acad. Sci. | pmid:2409860 |
Sage SO and Rink TJ | Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets. | 1985 | FEBS Lett. | pmid:2410292 |
Grandel KE et al. | Association of platelet-activating factor with primary acquired cold urticaria. | 1985 | N. Engl. J. Med. | pmid:2410790 |
Bussolino F et al. | Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. | 1985 | J. Immunol. | pmid:2411812 |
Johnson HM and Torres BA | Mechanism of calcium ionophore A23187-induced priming of bone marrow-derived macrophages for tumor cell killing: relationship to priming by interferon. | 1985 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2412225 |
Shen TY et al. | Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. | 1985 | Proc. Natl. Acad. Sci. U.S.A. | pmid:2983307 |
Pannocchia A and Hardisty RM | Cyclic AMP inhibits platelet activation independently of its effect on cytosolic free calcium. | 1985 | Biochem. Biophys. Res. Commun. | pmid:2983714 |